Association of Ocular Hypotensive Medication Types with Dynamic Contour Tonometry and Goldmann Applanation Tonometry Measurements in a Glaucoma and Ocular Hypertensive Population

Tzamalis, Argyrios; Kynigopoulos, Myron; Chalvatzis, Nikolaos; Dimitrakos, Stavros; Schlote, Torsten

doi:10.1089/jop.2012.0115

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in glaucomatous eye(s), this correlation is variable. Although it is widely known that IOP measurement using DCT is not significantly influenced by CCT compared with GAT, previous studies have reported that both GAT and DCT measurement values demonstrate significant correlation with CCT [ 21 , 22 ] or non-significant correlation with CCT in glaucomatous eyes [ 23 , 24 ]. CC is also affected by IOP measurement method.…”

Section: Discussionmentioning

confidence: 99%

Utility of Goldmann applanation tonometry for monitoring intraocular pressure in glaucoma patients with a history of laser refractory surgery

et al. 2018

View full text Add to dashboard Cite

The utility of Goldmann applanation tonometry (GAT) for monitoring intraocular pressure (IOP) in open-angle glaucoma (OAG) patients with a history of laser refractive surgery was investigated by comparing IOP fluctuations measured using GAT and dynamic contour tonometry (DCT) on the same day. In this retrospective study, patients were divided into one of two subgroups according to IOP fluctuation values using GAT: 43 eyes in the low IOP fluctuation group (LIFG [GAT fluctuation ≤1.7 mmHg]); and 55 eyes in the high IOP fluctuation group (HIFG [GAT fluctuation >1.7 mmHg]). IOP fluctuation was defined as the standard deviation of all IOP values during follow-up. IOP parameters using GAT were compared with those of DCT. Correlation analyses were performed among IOP parameters, and between IOP fluctuation and associated factors including central corneal thickness, corneal curvature, and axial length. All IOP parameters demonstrated significantly high values in the HIFG compared with those in the LIFG. Mean and peak IOP using DCT were significantly higher than those using GAT in both groups. However, there were no significant differences in IOP fluctuation and reduction using both tonometry methods in the HIFG (p = 0.946 and p = 0.986, respectively). Bland-Altman analysis revealed similar fluctuations using GAT and DCT. In multivariate analyses, there was a significant correlation between fluctuations using GAT and DCT in the HIFG (p = 0.043). These results suggest that IOP monitoring using GAT is a reliable method of monitoring IOP change in glaucoma patients with a history of laser refractive surgery, especially those exhibiting high IOP fluctuation. Nevertheless, several factors, including central corneal thickness, corneal curvature, and axial length, should be considered when using GAT for IOP monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of Goldmann applanation tonometry for monitoring intraocular pressure in glaucoma patients with a history of laser refractory surgery

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Administration of topical CAIs either as monotherapy or in combination with other IOP-lowering medications resulted in a significantly greater difference in IOP measured by dynamic contour tonometry (DCT) and Goldmann applanation tonometry (GAT). The diagnosis type (OAG or OHT) and the number of IOP-lowering medications had no significant influence on the difference in IOP as measured using the two instruments [13]. Dorzolamide/timolol and brinzolamide/timolol FCs effectively decreased IOP, which was a lower target IOP with dorzolamide/timolol than with brinzolamide/timolol, in patients with primary OAG or normal tension glaucoma [44].…”

Section: Resultsmentioning

confidence: 88%

“…In comparison, a triple PF tafluprost with PF dorzolamide/timolol FC resulted in a significant improvement in 24-hour IOP control as compared to the latanoprost baseline treatment [38]. Administration of CAIs either as monotherapy or in combination with other IOP-lowering medications resulted in a statistically significant difference in IOP measured by DCT and GAT [13].…”

Section: Carbonic Anhydrase Inhibitorsmentioning

confidence: 89%

“…Elevated intraocular pressure (IOP) [5,6] and older age [7][8][9] are the most important risk factors for the development and progression of primary OAG, of which only IOP is a modifiable factor [10]. Other risk factors include a family history of glaucoma [8,11,12], African American ancestry [13,14], systemic disease [15], thinner corneas [16], myopia [17], and steroid use [18]. Since IOP is the only modifiable risk factor, management of primary OAG has focused on decreasing IOP, which can delay disease progression, decrease the visual field (VF) loss rate, and protect against visual function loss and vision loss [19].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmaceutical treatment of primary open angle glaucoma

Al-Namaeh¹

2021

Med Hypothesis Discov Innov Optom

View full text Add to dashboard Cite

Background: Glaucoma is a progressive, irreversible optic neuropathy that results in serious vision loss and blindness. This review aimed to summarize key concepts of primary open angle glaucoma (POAG) pharmaceutical treatment trials over the last decade. Methods: We searched PubMed/MEDLINE and clinicaltrials.gov from January 1, 2010, to August 31, 2020, using the key words “POAG” and “Ocular topical therapeutics”. This search yielded 77 and 120 papers, respectively. Results: Thirty-three records were compatible with our inclusion criteria. Pharmaceutical treatment is a common intervention in POAG for lowering IOP. Prostaglandin (PG) analogues are most commonly recommended as initial medical therapy, which are administrated either as a monotherapy or in combination with other IOP-lowering classes of medications. Alternative therapies, such as ?-blockers, ?-2 adrenergic receptor agonists, and topical carbonic anhydrase inhibitors, have been used in combination or as a monotherapy. Rho-kinase inhibitors, such as netarsudil 0.02%, AR-13324 0.02%, and ripasudil are new IOP-lowering medications. Despite IOP reduction, there is a significant number of patients with POAG that may experience disease progression, and the risk of blindness over the long term is considerable. Conclusions: Clinical trials have indicated that pharmaceutical treatment of POAG is effective and safe. In addition, the new novel Rho-kinase inhibitors have shown significant IOP reduction. The new fixed combinations have also yielded significant reductions in IOP. POAG is a cause of irreversible vision loss, if not diagnosed and treated early. The condition is likely to progress in a significant number of patients, with a considerable risk of blindness in the long-term. How to cite this article: Al-Namaeh M. Pharmaceutical treatment of primary open angle glaucoma. Med Hypothesis Discov Innov Optom. 2021 Spring; 2(1): 8-17. DOI: https://doi.org/10.51329/mehdioptometry120

show abstract

Impact of corneal parameters on intraocular pressure measurements in different tonometry methods

2019

View full text Add to dashboard Cite

Association of Ocular Hypotensive Medication Types with Dynamic Contour Tonometry and Goldmann Applanation Tonometry Measurements in a Glaucoma and Ocular Hypertensive Population

Cited by 5 publications

References 32 publications

Utility of Goldmann applanation tonometry for monitoring intraocular pressure in glaucoma patients with a history of laser refractory surgery

Utility of Goldmann applanation tonometry for monitoring intraocular pressure in glaucoma patients with a history of laser refractory surgery

Pharmaceutical treatment of primary open angle glaucoma

Impact of corneal parameters on intraocular pressure measurements in different tonometry methods

Contact Info

Product

Resources

About